How to Build an AI Governance Committee in Healthcare

Artificial intelligence is moving quickly across healthcare, pharma, digital health, and life sciences. As more organizations adopt AI tools, one question is becoming increasingly important:

Who is responsible for deciding whether an AI tool should be used, how it should be monitored, and what happens when concerns arise?

That is where an AI governance committee becomes essential.

A healthcare AI governance committee provides the structure organizations need to evaluate AI tools, manage risk, define accountability, and support responsible implementation. Without this structure, AI adoption can become fragmented, inconsistent, and difficult to oversee.

For leaders, the goal is not to create bureaucracy. The goal is to create a practical decision-making body that helps the organization use AI safely, responsibly, and effectively.

Healthcare Leadership Team

Why Healthcare Organizations Need an AI Governance Committee

AI can affect clinical care, operations, research, documentation, patient engagement, revenue cycle, trial recruitment, and business strategy. Even tools that appear administrative can influence access, quality, safety, privacy, equity, and trust.

An AI governance committee helps organizations answer key questions:

• Which AI tools are currently in use?

• Which AI tools require review before deployment?

• Who approves high-risk AI use cases?

• How should AI vendors be evaluated?

• What evidence is needed before implementation?

• How will performance, bias, and safety be monitored?

• Who is accountable when an AI tool does not perform as expected?

  
  

The NIST AI Risk Management Framework emphasizes that AI risk management should include governance, mapping, measurement, and management processes across the AI lifecycle. For healthcare organizations, a committee can help translate those principles into operational practice.

Start With a Clear Purpose

Before forming a committee, organizations should define its purpose.

An AI governance committee should not exist only to discuss AI broadly. It should have a clear mandate tied to risk, oversight, and implementation.

A practical committee's purpose may include:

• reviewing proposed AI use cases

• classifying AI tools by risk level

• evaluating vendor evidence and validation

• assessing privacy, security, bias, and equity risks

• defining human oversight requirements

• approving deployment of higher-risk tools

• monitoring AI performance after implementation

• reviewing incidents, concerns, or unintended consequences

• recommending updates, restrictions, or retirement of AI tools

  
  

The more specific the committee’s role, the more useful it becomes.

Include the Right People

Healthcare AI governance should not sit only with data science or technology teams. AI risk is clinical, operational, legal, ethical, regulatory, and strategic.

A strong AI governance committee should include representation from:

• clinical leadership

• operations

• compliance

• legal

• privacy and security

• data science or analytics

• quality and patient safety

• health equity

• research or clinical trials

• procurement

• frontline users

• executive leadership

  
  

For pharma and life sciences organizations, additional representation may be needed from clinical development, medical affairs, regulatory affairs, pharmacovigilance, real-world evidence, and commercial teams.

The goal is to bring the right expertise into the room before deployment decisions are made.

Define Decision Rights

One of the most common weaknesses in AI governance is unclear authority.

A committee may review an AI tool, but who has the authority to approve it? Who can pause deployment? Who decides whether a model needs additional validation? Who owns monitoring after launch?

These decision rights should be defined early.

Organizations should clarify:

• which AI tools require committee review

• which tools can be approved through a lower-risk pathway

• who has final approval authority

• who owns implementation

• who owns post-deployment monitoring

• who receives performance reports

• who can escalate safety, fairness, or compliance concerns

• who decides when an AI tool should be modified, restricted, or retired

Without clear decision rights, governance becomes advisory without being operational.

Create a Standard Review Process

An AI governance committee needs a repeatable process for reviewing AI tools.

This process should be clear enough for teams to use, but flexible enough to account for different levels of risk.

A practical review process may include:

1. AI intake form

   Captures the tool, vendor, intended use, users, data inputs, outputs, and affected stakeholders.

2. Risk tiering

   Classifies tools based on clinical, operational, privacy, equity, and patient safety impact.

3. Evidence review

   Evaluates validation data, performance metrics, limitations, and external evidence.

4. Bias and fairness assessment

   Reviews whether the tool performs consistently across relevant populations and settings.

5. Privacy and security review

   Assesses data use, storage, sharing, cybersecurity, and contractual terms.

6. Workflow assessment

   Determines how the tool will fit into clinical or operational processes.

7. Monitoring plan

   Defines metrics, reporting cadence, escalation triggers, and accountability.

8. Approval decision

   Documents whether the tool is approved, approved with conditions, deferred, or rejected.

   
   

This process supports consistent, defensible decision-making.

Match Oversight to Risk

Not every AI tool needs the same level of review.

A generative AI tool used for internal brainstorming may carry a different risk than an AI model used for clinical triage, diagnosis, treatment recommendations, trial eligibility, or patient outreach.

The committee should define risk tiers that determine the level of oversight required.

Lower-risk tools may require basic documentation, privacy review, and acceptable-use guidance. Higher-risk tools may require clinical validation, subgroup performance review, legal review, executive approval, and ongoing monitoring.

This risk-based approach helps organizations avoid two common mistakes: under-governing high-risk tools and overburdening low-risk innovation.

Build Monitoring Into the Committee’s Work

AI governance does not end when a tool is approved.

Model performance can change over time. Patient populations shift. Workflows evolve.

Vendor tools are updated. New risks can emerge after deployment.

The committee should oversee post-deployment monitoring for higher-risk AI tools, including:

• model performance

• subgroup performance

• false positives and false negatives

• workflow impact

• user adoption and override patterns

• incident reports

• patient safety signals

• bias or equity concerns

• model drift

• vendor updates

The WHO has emphasized that AI for health requires governance approaches that protect safety, autonomy, transparency, equity, and accountability. Ongoing oversight is central to that work.

Address Shadow AI

An AI governance committee should also address shadow AI.

Shadow AI occurs when staff use AI tools outside approved policies, systems, or governance pathways. This is increasingly relevant as generative AI tools become easier to access and use.

A committee can help define:

• approved and prohibited AI uses

• whether patient or confidential data may be entered into AI tools

• documentation expectations

• human review requirements

• vendor approval pathways

• staff training requirements

• escalation processes for uncertain use cases

The goal is not to block innovation. The goal is to make responsible AI use easier than unauthorized use.

Make the Committee Practical

An AI governance committee should be designed for action.

If the committee is too large, too slow, or too disconnected from operational workflows, teams may bypass it. If it is too informal, it may not manage risk effectively.

To make the committee useful, organizations should define:

• meeting cadence

• review timelines

• required documentation

• risk tiering criteria

• approval pathways

• escalation processes

• reporting structure

• ownership of follow-up actions

• relationship to existing compliance, quality, data, and innovation committees

  
  

The committee should be rigorous enough to manage risk, but practical enough to support responsible adoption.

What Leaders Should Do Now

Healthcare and life sciences leaders can begin by asking five questions:

1. Do we have a formal process for reviewing AI tools before deployment?

2. Do we know who has authority to approve or reject AI use cases?

3. Do we have the right clinical, technical, legal, privacy, and operational expertise involved?

4. Do we monitor AI tools after they go live?

5. Do we have a clear process for addressing AI-related concerns or incidents?

If the answer to any of these questions is unclear, an AI governance committee may be needed.

Responsible AI Requires Clear Accountability

AI governance is not only about principles. It is about operational accountability.

A well-designed AI governance committee helps organizations evaluate AI tools consistently, manage risk, support responsible innovation, and build trust with clinicians, patients, regulators, and partners.

The organizations that lead in healthcare AI will not simply be those that adopt AI fastest.

They will be the organizations that can show who is accountable, how decisions are made, and how AI is monitored in practice.

Need Support Building an AI Governance Committee?

CROSS Global Research & Strategy advises healthcare, pharma, digital health, and life sciences organizations on responsible AI strategy, governance, validation, and implementation.

We help teams design AI governance committees, define decision rights, create review workflows, evaluate AI risk, and build oversight structures that support patient safety, equity, trust, and regulatory readiness.

To discuss how your organization can strengthen AI governance and accountability, contact CROSS Global Research & Strategy.

Schedule an AI governance consultation

Suggested References

1. National Institute of Standards and Technology. Artificial Intelligence Risk Management Framework (AI RMF 1.0). National Institute of Standards and Technology; 2023.

2. World Health Organization. Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. World Health Organization; 2021.

3. Coalition for Health AI. Blueprint for Trustworthy AI Implementation Guidance and Assurance for Healthcare. Coalition for Health AI; 2023.

4. The Joint Commission; Coalition for Health AI. The Responsible Use of AI in Healthcare. 2025.

5. URAC. Health Care AI: Accountability in Practice. URAC; 2026.